Southern Christian Leadership Conference

(redirected from SCLC)
Also found in: Dictionary, Legal, Acronyms, Wikipedia.
Related to SCLC: SNCC

Southern Christian Leadership Conference

(SCLC), civil-rights organization founded in 1957 by Martin Luther KingKing, Martin Luther, Jr.,
1929–68, American clergyman and civil-rights leader, b. Atlanta, Ga., grad. Morehouse College (B.A., 1948), Crozer Theological Seminary (B.D., 1951), Boston Univ. (Ph.D., 1955).
..... Click the link for more information.
, Jr., and headed by him until his assassination in 1968. Composed largely of African-American clergy from the South and an outgrowth of the Montgomery, Ala., bus boycott that King had led, it advocated nonviolent passive resistance as the means of securing equality for African Americans. It sponsored the massive march on Washington in 1963. Ralph AbernathyAbernathy, Ralph David
, 1926–90, American civil-rights leader, b. Linden, Ala. A Baptist minister, he helped Martin Luther King, Jr., organize the Montgomery bus boycott (1955).
..... Click the link for more information.
 headed (1968–77) the SCLC after King's death, but it since has become less prominent. The SCLC continues to sponsor a number of programs, including voter registration and education and the Truth and Justice Campaign.
The Columbia Electronic Encyclopedia™ Copyright © 2013, Columbia University Press. Licensed from Columbia University Press. All rights reserved. www.cc.columbia.edu/cu/cup/
References in periodicals archive ?
Rova-T is an investigational antibody-drug conjugate targeting the cancer-stem cell-associated delta-like protein 3 (DLL3)[1], which is expressed in more than 80 percent of small-cell lung cancer (SCLC) patient tumors, where it is prevalent on tumor cells, including cancer stem cells, but not present in healthy tissue.[2] Rova-T combines a targeted antibody with a cytotoxic agent that is delivered directly to the DLL3-expressing cancer cells.
In June 2019, the Phase III CASPIAN trial met its primary endpoint with Imfinzi by showing a statistically-significant and clinically-meaningful improvement in overall survival for patients with extensive-stage SCLC. These patients were treated with Imfinzi in combination with standard-of-care etoposide and platinum-based chemotherapy vs.
Imfinzi is also being tested following concurrent chemoradiation therapy in limited-stage SCLC in the phase III ADRIATIC trial.
Large cell neuroendocrine carcinoma (LCNC) is one example of lung large cell carcinoma (LCC), that shares the same characteristics with small cell lung cancer (SCLC) such as massive proliferation rates and neuroendocrine phenotype but lacks cytomorphology of SCLC (79, 80).
Standard treatment for advanced SCLC is chemotherapy, but recurrence is common and the average survival is only about 12 months, according to Byers.
One reason for the lack of new treatments is the rapid onset and progression of SCLC, making it difficult to obtain clinical samples for researchers to study.
He said a former teacher of the school has executed an affidavit to prove the claim that SCLC has links with the New People's Army (NPA).
Our study confirmed repeat PTNB was the effective way to fully understand the mechanisms of resistance and to allow discrimination of tumors with SCLC transformation.[2] The NGS results of consecutive repeat biopsy samples, which showed the presence of TP53 C176S and EGFR ex19del and the same change trend shared by them, confirmed that SCLC transformation is one caused by a phenotypic switch that originates from the common cell type rather than intratumor heterogeneity.
Small-cell lung cancer (SCLC) is an aggressive neuroendocrine subtype of lung cancer and is associated with paraneoplastic syndromes in about 20 to 40% of cases [1,2].
Here we report the unique presentation, challenging diagnosis, and successful management of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) coexisting in the same patient.